MARKSANS PHARMA
|
|
BOM : 524404     NSE : MARKSANS     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Dec 20,2024 |
Price(EOD): ₹ 303.65
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 13,761.42 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
MARKSANS PHARMA | -2.7% | -1.7% | 97.1% |
SUN PHARMACEUTICAL INDUSTRIES | -0.1% | 1.7% | 45.7% |
CIPLA | 1.7% | 0.5% | 23.7% |
DR REDDYS LABORATORIES | 5.7% | 12.4% | 18.5% |
ZYDUS LIFESCIENCES | -1.4% | 3.1% | 44.8% |
DIVIS LABORATORIES | -0.1% | -2.2% | 56.9% |
MANKIND PHARMA | 4.2% | 9.8% | 49.8% |
TORRENT PHARMACEUTICALS | 2.2% | 10.6% | 61.7% |
LUPIN | 4.1% | 5.1% | 71.7% |
FUNDAMENTAL ANALYSIS OF MARKSANS PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF MARKSANS PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
39.61
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 347.44 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 6.66
P/B Calculated based on Book Value of Rs 2,065.05 Cr
[Latest Year - Mar2024 - Consolidated Results ] 5.78
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 2,378.68 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
326% 227% 269% |
SHARE PRICE MOMENTUM OF MARKSANS PHARMA
MARKSANS PHARMA vs SENSEX
DEBT OF MARKSANS PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0.01 - |
0.01 0.02 0.04 0.02 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF MARKSANS PHARMA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF MARKSANS PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
8.69% 5.64% 3.82% 9.76% |
20.84% 19.07% 9.52% 16.59% |
QtrlyTrend |
8 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
MARKSANS PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 0.1% | 4% | 45% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE SMALL CAP | -3.2% | 5.1% | 31.1% |
S&P BSE MIDSMALLCAP | -3.2% | 4.4% | 29.5% |
You may also like the below Video Courses
FAQ about MARKSANS PHARMA
Is MARKSANS PHARMA good for long term investment?
As on Dec 20,2024, the Fundamentals of MARKSANS PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of MARKSANS PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is MARKSANS PHARMA UnderValued or OverValued?
As on Dec 20,2024, MARKSANS PHARMA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of MARKSANS PHARMA ?
As on Dec 20,2024, the Intrinsic Value of MARKSANS PHARMA is Rs. 82.37 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 71.34
Fair Value [Median EV / Sales Model] : Rs. 92.88
Fair Value [Median Price / Sales Model] : Rs. 82.37
Estimated Median Fair Value of MARKSANS PHARMA : Rs. 82.37
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.